Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease, or PVD, and local oncology therapy options for treating cancer, including radiofrequency ablation, or RFA, systems, NanoKnife Ablation Systems, surgical resection systems and embolization products for treating benign and malignant tumors. We design, develop, manufacture and market a broad line of therapeutic and diagnostic devices that enable interventional physicians (interventional radiologists, vascular surgeons, surgical oncologists and others) to treat PVD, tumors, and other non-coronary diseases. Unlike several of our competitors that focus on the treatment of coronary diseases, we believe that we are the only company whose primary focus is to offer a comprehensive product line for the interventional treatment of PVD, tumors and other non-coronary diseases. We have been in business since 1988. ... More ...
Analyst Info |
|
| Annual EPS Est: | $0.43 |
| Quarterly EPS Est: | 0.05 |
| PEG Ratio: | 2.09 |
|
Mean Recommendation: View Summary / View All |
2.33 |
Data is provided by Zacks Investment Research
